GlassScriptPhysician profile
Tristan T Lai
NPI 1699976217
$23,966.21
in general payments reported to CMS, 2019-2025
30 companies · $8,672 in 2025
The $8,672 reported for 2025 was more than what 94% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,096 · 2020: $1,337 · 2021: $2,230 · 2022: $4,405 · 2023: $2,343 · 2024: $3,885 · 2025: $8,672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,800 · Food and Beverage: $6,612 · Travel and Lodging: $1,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,800.00 |
| Food and Beverage | $6,612.13 |
| Travel and Lodging | $1,487.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $15,844.73 | 2019-2025 | Proclaim, Eterna, Ionicrf |
| Boston Scientific Corporation | $2,677.62 | 2019-2025 | Intracept, Intracept Rf Probe, General - Pain Management |
| Medtronic, INC. | $2,170.28 | 2021-2025 | Synchromedii |
| Relievant Medsystems, INC. | $502.63 | 2022-2023 | Intracept |
| Si-Bone, INC. | $399.89 | 2020-2024 | |
| Saluda Medical Americas, INC. | $362.21 | 2023-2025 | Evoke, Evoke Scs |
| Nevro Corp. | $337.67 | 2019-2024 | Senza |
| Medtronic USA, INC. | $206.99 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $167.02 | 2020-2025 | Belbuca, Xtampza |
| Abbvie INC. | $164.83 | 2022-2023 | |
| Spr Therapeutics, INC | $143.95 | 2024-2025 | Sprint Pns System |
| Globus Medical, INC. | $139.20 | 2025 | Senza |
| Vertiflex, INC. | $86.83 | 2019 | |
| Nalu Medical, INC. | $84.11 | 2021-2024 | Nalu Neurostimulation System |
| Biotronik Nro, INC. | $83.29 | 2024 | Prospera |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.92 | 2019-2025 | Relistor |
| Teva Pharmaceuticals USA, INC. | $80.91 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $62.21 | 2024 | |
| Allergan, INC. | $59.52 | 2022 | |
| Pfizer INC. | $49.23 | 2020 | |
| Grt US Holding, INC. | $47.77 | 2021-2022 | |
| Almatica Pharma LLC | $40.97 | 2021 | |
| Orthogenrx INC. | $38.86 | 2019 | |
| Vertos Medical, INC. | $38.19 | 2023 | Mild Device Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $25.11 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $19.10 | 2025 | |
| Daiichi Sankyo INC. | $14.26 | 2019 | |
| Redhill Biopharma INC. | $13.17 | 2021 | |
| Mdd US Operations, LLC | $11.73 | 2022 | |
| Assertio Therapeutics, INC. | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tristan Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.